CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026
$300.02−0.13 (-0.04%)
Close on Oct 19, 2026
- Market cap
- $14.41B
- P/E (TTM)
- –
- Dividend yield
- –
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DSA | $2.40B | $2.45B | $2.62B | $2.45B | – | – | – | – | – | – | 59.8% | -2.0% |
| RMS | $846.08M | $829.38M | $792.34M | $739.18M | – | – | – | – | – | – | 21.1% | +2.0% |
| Manufacturing | $766.41M | $769.33M | $721.44M | $789.57M | – | – | – | – | – | – | 19.1% | -0.4% |
| RMS | – | $829.38M | $792.34M | $739.18M | $690.44M | $571.15M | $537.09M | $519.68M | $493.62M | $494.04M | – | – |
| Manufacturing | – | – | $721.44M | $789.57M | $742.49M | $515.35M | $465.14M | $429.56M | $383.96M | $350.80M | – | – |
| DSA | – | – | $2.62B | $2.45B | $2.11B | $1.84B | $1.62B | $1.32B | $980.02M | $836.59M | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DSA | $424.56M | $442.51M | $606.08M | $532.89M | – | – | – | – | – | – | -4.1% |
| Segment operating income | $284.84M | $485.47M | $849.07M | $860.38M | – | – | – | – | – | – | -41.3% |
| RMS | $44.57M | $114.41M | $154.67M | $160.41M | – | – | – | – | – | – | -61.0% |
| Manufacturing | -$184.28M | -$71.45M | $88.33M | $167.08M | – | – | – | – | – | – | +157.9% |
| RMS | – | – | $154.67M | $160.41M | $166.81M | $102.71M | $133.91M | $136.47M | $114.59M | $136.42M | – |
| Manufacturing | – | – | $88.33M | $167.08M | $246.39M | $181.49M | $145.42M | $136.21M | $123.90M | $104.56M | – |
| DSA | – | – | $606.08M | $532.89M | $406.98M | $325.96M | $258.90M | $227.58M | $182.80M | $135.38M | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of services provided (excluding amortization of intangible assets) | $3.25B | $3.30B | $3.44B | $3.22B | $2.76B | $2.30B | $2.03B | $1.69B | $1.30B | $1.13B | 80.9% | -1.6% |
| Product | $765.28M | $745.85M | $689.39M | $759.16M | $784.58M | $627.78M | $591.86M | $578.16M | $559.30M | $550.70M | 19.1% | +2.6% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $2.14B | $2.24B | $2.35B | $2.34B | $1.93B | $1.63B | $1.47B | $1.27B | $959.26M | $850.42M | 53.3% | -4.4% |
| Europe | $1.10B | $1.08B | $1.08B | $1.03B | $1.04B | $829.31M | $726.42M | $643.96M | $569.81M | $520.94M | 27.5% | +2.3% |
| Canada | $501.03M | $482.09M | $487.31M | $398.98M | $339.10M | $306.26M | $271.99M | $206.38M | $200.34M | $194.21M | 12.5% | +3.9% |
| Asia Pacific | $205.02M | $196.95M | $200.83M | $192.84M | $222.90M | $155.09M | $146.22M | – | – | – | 5.1% | +4.1% |
| Other | $64.87M | $52.82M | $16.85M | $9.96M | $7.29M | $6.13M | $5.50M | $5.64M | $1.72M | $1.15M | 1.6% | +22.8% |
| Other Non-U.S. | – | – | – | – | – | – | – | – | – | $69.03M | – | – |
| Japan | – | – | – | – | – | $155.09M | $146.22M | $142.50M | $126.46M | $114.71M | – | – |
From the segment and revenue-disaggregation notes of Charles River Laboratories International's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.